BiVictriX Therapeutics PLC BiVictriX Director Dealing (1106E)
March 09 2022 - 2:01AM
UK Regulatory
TIDMBVX
RNS Number : 1106E
BiVictriX Therapeutics PLC
09 March 2022
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
9 March 2022
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or "the Company")
Director Dealing
Alderley Park, 9 March 2022 BiVictriX Therapeutics plc (AIM:
BVX), an emerging biotechnology company applying a novel approach
to develop next generation cancer therapies using insights derived
from frontline clinical experience, today announces the following
dealing in the Company's ordinary shares of 1 pence each ("Ordinary
Shares").
On 8 March 2022, 100,000 Ordinary Shares at a price of 22.25
pence each were purchased by Iain Ross, Chairman of the Company,
through his self-invested personal pension (SIPP).
Following this purchase, Mr Ross is benefically interested in
400,000 Ordinary Shares representing 0.61 per cent of the Company's
total issued share capital.
-Ends-
For more information, please contact: BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer Email: info@bivictrix.com
Iain Ross, Chairman
SP Angel Corporate Finance LLP (NOMAD
and Broker) Tel: +44 (0) 20 3470
0470
David Hignell, Caroline Rowe (Corporate
Finance)
Vadim Alexandre, Rob Rees (Sales and
Broking)
Panmure Gordon (UK) Limited (Joint Broker) Tel: +44 (0) 20 7886 2500
Rupert Dearden/Freddy Crossley/Emma Earl
Consilium Strategic Communications
Mary-Jane Elliott, Genevieve Wilson, Tel: +44 (0) 20 3709 5700
Alex Gunter Email: Bivictrix@consilium-comms.com
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company
which is focused on leveraging clinical experience to develop a
class of highly selective, next generation cancer therapeutics
which exhibit superior potency, whilst eliminating
treatment-related toxicities.
The Company utilises a first-in-class approach to generate a
proprietary pipeline of Bi-Cygni(R) therapeutics which are designed
to selectively target antigen co-expression fingerprints, or "twin
antigens", on tumour cells, which are largely absent from healthy
cells. Whereas this concept has been validated in a clinical
diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a
therapeutic setting.
BiVictriX has identified a diverse panel of novel
cancer-specific "twin antigens", across a broad range of cancer
indications including Diffuse Large B Cell Lymphoma, Acute Myeloid
Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The
Company is using these novel "twin-antigens" to develop more
effective and safer therapeutics to target cancers that are
expected to constitute orphan indications and currently constitute
areas of high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Iain Ross
------------------------------- --------------------------------------
2. Reason for the Notification
-----------------------------------------------------------------------
a) Position/status Non-Executive Chairman
------------------------------- --------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- --------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name BiVictriX Therapeutics plc
------------------------------- --------------------------------------
b) LEI 213800ZI85IZNA6N3L53
------------------------------- --------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the Financial GB00BNXH3K91
instrument, type
of instrument
Identification
code
------------------------------- --------------------------------------
b) Nature of the Purchase of Ordinary Shares via
transaction SIPP
------------------------------- --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) 22.25 p 100,000
----------
------------------------------- --------------------------------------
d) Aggregated information: Price(s) Volume(s)
* Aggregated volume 22.25p 100,000
----------
* Price
------------------------------- --------------------------------------
e) Date of the transaction 8 March 2022
------------------------------- --------------------------------------
f) Place of the AIM, London Stock Exchange
transaction
------------------------------- --------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDDGDXCBGDGDI
(END) Dow Jones Newswires
March 09, 2022 02:01 ET (07:01 GMT)
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Apr 2023 to Apr 2024